Login to Your Account



Phase II Clinical Trials Update: October 2011


Monday, November 14, 2011

Company (Location)

Product

Description

Indication

Status (Date)#


AUTOIMMUNE

Alvine Pharmaceuticals Inc. (San Carlos, Calif.)

ALV003

An oral mixture of recombinant gluten-specific proteases cysteine protease and prolyl endopeptidase

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription